Annals of medicine · 2025
Bleeding risk and prediction model to predict bleeding risk of tissue biopsy for definitive diagnosis in patients with suspected amyloidosis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uraiwan Watsamon, Saelue Pirun
Аннотация
INTRODUCTION: Bleeding from the affected organs is a common manifestation of amyloidosis. The risk for perioperative bleeding in patients with amyloidosis remains controversial. In this study, we aimed to compare the bleeding risk of tissue biopsies for a definitive diagnosis between patients with and without amyloidosis, identify risk factors, and generate a prediction model for bleeding risk in these patients.
METHODS: We enrolled patients aged >15 years who had amyloidosis as part of their differential diagnosis before tissue biopsy. After obtaining histopathological reports, we randomly selected patients with and without amyloidosis at a ratio of 4:1.
RESULTS: A total of 360 patients were enrolled before tissue biopsy. Bleeding complications were observed in 5.6% and 4.2% of patients with and without amyloidosis, respectively. Amyloidosis was not associated with an increased perioperative bleeding risk (adjusted odds ratio 1.19; 95% confidence interval 0.17-8.41, p = 0.859). Kidney biopsy was a significant risk factor for perioperative bleeding in tissue biopsies. A KiHPL model was generated to predict the bleeding risk. The area under the curve was 0.87, with a good calibration plot for this model.
CONCLUSIONS: Amyloidosis is not associated with an increased risk of bleeding in tissue biopsies. The KiHPL model can predict the bleeding risk of tissue biopsies for a definitive diagnosis in patients with suspected amyloidosis.
METHODS: We enrolled patients aged >15 years who had amyloidosis as part of their differential diagnosis before tissue biopsy. After obtaining histopathological reports, we randomly selected patients with and without amyloidosis at a ratio of 4:1.
RESULTS: A total of 360 patients were enrolled before tissue biopsy. Bleeding complications were observed in 5.6% and 4.2% of patients with and without amyloidosis, respectively. Amyloidosis was not associated with an increased perioperative bleeding risk (adjusted odds ratio 1.19; 95% confidence interval 0.17-8.41, p = 0.859). Kidney biopsy was a significant risk factor for perioperative bleeding in tissue biopsies. A KiHPL model was generated to predict the bleeding risk. The area under the curve was 0.87, with a good calibration plot for this model.
CONCLUSIONS: Amyloidosis is not associated with an increased risk of bleeding in tissue biopsies. The KiHPL model can predict the bleeding risk of tissue biopsies for a definitive diagnosis in patients with suspected amyloidosis.